MEDICAL BREAKTHROUGHS
Untitled Page
ADVTX product shows revolutionary promise
Fibrinoplate-S has shown efficacy in reducing the bleeding in animals exposed to extreme radiation.
By Susan BelknappPublished: July 16, 2009 04:15 AM
Anaheim-based Advanced Therapeutics & Co. (ADVTX) announced today that Fibrinoplate-S has shown notable promise in reducing the bleeding in animals exposed to extreme doses of radiation. This is particularly significant of survivors of a nuclear event or a dirty bomb explosion will have similar damage from the ionizing radiation of such bombs.
Fibrinoplate-S a viable alternative to platelet transfusion for survivors of near-lethal doses of radiation
“Acute radiation can severely damage the bone marrow,” says Richard Yen, Ph.D., M.D., CEO of ADVTX. “While existing medications can boost the production of red cells and white cells from the recovering bone marrow, there is no effective treatment for low concentrations of platelets except through platelet transfusion. Donor platelets, however, may not be available or adequately screened for pathogens during times of distress.”
NEXT PAGE >>
Related headlines
PacSun Pipeline to a Cure planned for Saturday at Huntington Beach Hyatt
ICU Medical acquires Hospira's critical care line
Hoag Hospital Breast Care Center receives prestigious designation
‘OC METRO Minute,’ July 9: Pipeline to a Cure event July 18
|
||||
|
Anaheim-based Advanced Therapeutics & Co. (ADVTX) announced today that Fibrinoplate-S has shown notable promise in reducing the bleeding in animals exposed to extreme doses of radiation. This is particularly significant of survivors of a nuclear event or a dirty bomb explosion will have similar damage from the ionizing radiation of such bombs. Fibrinoplate-S a viable alternative to platelet transfusion for survivors of near-lethal doses of radiation “Acute radiation can severely damage the bone marrow,” says Richard Yen, Ph.D., M.D., CEO of ADVTX. “While existing medications can boost the production of red cells and white cells from the recovering bone marrow, there is no effective treatment for low concentrations of platelets except through platelet transfusion. Donor platelets, however, may not be available or adequately screened for pathogens during times of distress.” NEXT PAGE >> Related headlines PacSun Pipeline to a Cure planned for Saturday at Huntington Beach Hyatt ICU Medical acquires Hospira's critical care line Hoag Hospital Breast Care Center receives prestigious designation ‘OC METRO Minute,’ July 9: Pipeline to a Cure event July 18 |
||||
